Ascendis Health has entered into agreements with a consortium comprising RMB Ventures Seven, Nedbank Private Equity and certain members of the management of the Ascendis Biosciences division for the sale of various businesses under its Biosciences division for R480-million. A strategic review of the division had determined that it was noncore to the group’s strategy.